IMUX - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to Immunic's First Quarter 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call.

Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President as well as Glenn Whaley, our recently promoted Chief Financial Officer. will recorded. listen-only participants event and all being is note be mode in this Please presentation, will today's After there questions. to ask be an opportunity

are the new questions. If via two there joined submit ways you to webcast platform, this

queue portal can [Operator the tool the question. like raise in Q&A a to hand You via with Instructions] us you Zoom or of submit function in Zoom your writing to either directly, question. the if speak portal to queue would your question please the use

ahead. for of to forward-looking revise President these results Immunic's more any to the of and or that Please to information the now like Before forward-looking SEC could materially these begin call release can forward-looking remind as may by description we future as and estimate, like publicly to the to cause Immunic's involves presentation that you factors refer Immunic's number filings obligation opinions to affect meaning statements reflect of a actual results to CEO statements. of such with detailed may this Daniel, turn similar Vitt, anticipate, such begin, I from note it events. in statements. that would or Daniel this discussed over these in revision presentation a and words that may, words differ be I or contain here. will, go forward-looking please our would the Please expect, statements light statements statements the risk date with Such only Immunic's no of risks to new a undertakes of uncertainties those presentation. results Dr. identified and

Daniel Vitt

results development earnings as Immunic's related welcome highlighted the to clinical Jessica. activities would pipeline. and recent our for announced call. financial quarter well I our quarter XXXX milestones as Thank to everybody March ended XXXX, this morning, we XXst, Earlier you, to like first upcoming

our through financial as subsequent we first highlights, quarter results, XXXX will as and During talk operating today's call, well milestones. and anticipated

you to of close As Jessica opportunity call, before questions. we the have will the noted, ask

of [Indiscernible] The XXXX quarter first marked by was continued

Operator

mute restart My second. review problem. can the like you quarter, of for apologies, little the had Maybe the I had audio seems with you a Daniel. It to a please.

Daniel Vitt

[Indiscernible]

Operator

a to No. not to audience. take line. Still My you with I'm would issue No, like the technical Maybe, the apologies over? working. Glenn, sure. not

Glenn Whaley

we'll Sure. Jessica. We'll do --

Glenn Whaley

XXXX, pipeline. earlier we So this our milestones and recent quarter financial morning, as as related activities for XXst, ended development results clinical our announced the upcoming well March highlighted to

our subsequent call, will operating first through and During as and quarter highlights, well today's XXXX walk milestones. we financial as results, anticipated

before questions. noted, the the Jessica have ask call, to As opportunity you close we

as including quarter first pipeline by The this clearing stated quarter, made, and XXXX within be is the progress key I across we financially The have year marked continued several last that advancement Immunic. in way the of readouts for was data business, transformative for programs. our important could

the at proinflammatory vidofludimus Let regulatory at t-cell calcium February, me 'XX Congress proinflammatory secretion in anti-inflammatory preclinical first included: and data In immune events cytokines macrophages, ECCO. calcium proliferation. the First, and reducing more inducing detail. of Highlights by potent activity XXth of quarter you we reducing reduces cell subsequent that the walk responses through presented vidofludimus

the the are receive patients blinded characteristics Congress also a were calcium is And XX% three conjunction Eco the endoscopic baseline In stimulus a pre disease. utilized Patients calcium criteria. modified the of to synergistic central that -treated in with important The the At active antibodies. of our a III and patients as vidofludimus CALDOSE-X trial patients anti-TNF XX% had pleased of evaluate Second, mayor we of finally, and see immune of we with biologics. the Phase you highly of severe were may of had trial fraction baseline, eligibility a noted, DHODH [Indiscernible] shows to active. announced trial strong additive metabolically only score score endoscopic to that independent recall, vidofludimus And had to in reader the effect as cell we moderate XX% with two.

we that and study As the to data randomized endoscopic previously regarding patient the noted, the contribute ensuring assessments trial optimized firmly used in believe readout. methodology to

could of safety along believe analysis, already and to colitis strong the tolerability continue ulcerative the We preferred that profile, treatment established suffering that from option oral and vidofludimus alternatives for to the drug calcium, biologics. interim become with a suggest patients results obvious

IL-XX development least the recently, targets In patients receipt cohorts IMU-XXX, we with with This and have preclinical can this IMU-XXX, an intestinal our our disease. the IMU-XXX to the epithelium. in for to patents important in XXXX. outstanding best-in-class maintaining first the restoration and in and clinical is promoted barrier These restore this March, immuno of of suggested the announced of this molecule, while at be in and of regeneration asset - regenerate us Australia. data In have the of position. we of with milestone patents matter Marking bolstered significantly protection, in available job intellectual third done asset, about we our start studies Phase potentially property He extension Most provide composition clinical that will celiac XXXX, inhibitor. protection gastrointestinal track the possible to U.S. X PTE allowances or and Pleased function notice potential as architecture trial function which the compency. patients second program intestinal Chief plan early our U.S. to barrier further our February, to from time, Officer. an small our of with Financial Europe, ongoing through clinical respectively. the Europe, patient treated oral has Moving IMU-XXX in SPC for in Whaley Glenn

the Moving financial on to results.

our then with with we subsequently, overview. and through additional cash cash equivalents Let at-the-market raised in the April, start facility. in first cash ended quarter an We million me the $XX million $XX.X and

Automated Voice

progress. in Recording

Glenn Whaley

cash to sufficient this be third to the operations of fund anticipate quarter XXXX. balance We into

approximately primarily to months $XX.X quarter $X to to was loss for March shares weighted $XX.X weighted per as as XXst, or administrative personnel ulcerative a share offset $XX.X for clinical increased period period of same or ended decrease clinical million share results; increase were our XXXX last as the as million well COVID-XX March the well the reflect X increases related increase XXXX quarter Regarding company's personnel in net $XX.X increase the the costs in in compared costs approximately ended million loss due ramp-up XXst, expenses expenses to million as the to partially support decreased to the based to same in research for for The drug based and programs for million smaller the shares of expenses growth. were supply the were outstanding costs in Phase XXst the General related and vidofludimus a in ended The categories. compared more trials for approximately million common outstanding $X.X on XXXX. expenses was average as and colitis on people per calcium. million expenses period $X.XX costs three related costs hiring our million across The Net to for the of $X.XX year. operating and three XXXX. $XX.X Compared numerous same continued quarter development average common in $XX.X XXXX clinical for March by

in enrollment vidofludimus on most II calcium of highly fourth upcoming CALDOSE-X one quarter inflection UC, our we the of Phase value the Moving will our during to trial anticipated completed moderate-to-severe of previously which notably patients year. having of important last be points reported readout with

a active XXX dosing and into the had randomized XX arms reminder, arms. as as Three completion patient of As trial of the XX, at total four milligrams, well a of placebo. patients recruitment, XX,

was with healthy safety, for as a this As severe previously psoriasis. IMU-XXX the mild first-time X for positive volunteer of unblinded reported 'XX key PD patients after and compound. portions the patients planned. ongoing trial represents having with as are milestone expanded PK Phase to trial in from include are IMU-XXX, to QX, to We portion a treated being third This treat it us data

fourth New to order press have in submitted has quarter randomization. to limitations we mentioned now regulatory call, order with in in related address and conducted, COVID-XX our authorities where forward exclusively documentation been required trial the patient Macedonia As the this Australia Zealand, North in in rapidly to and Bulgaria

We a at first expect population. provide available initial in data results be patient trial the and from efficacy IMU-XXX this this will with initial year. profile third portion look of to of the us important half this second safety The in

of by of metastatic in principal in experts trial, of year. In castration-resistant this Bono, have is De data CRPC. the We're Phase been addition, grateful IMU-XXX ongoing. third dose subject of QX XXXX, and Dr. of enrollment initiated initial prostate escalation in Sebastian the trial in The that trial Johann of I led on helm be progressive cancer, de safety one available which anticipate quarter foremost has investigator world's was at this to Dr. the will late the the Bono

of these indication. XXXX. sclerosis is bit recommended I of multiple-ascending healthy with relapsing biomarkers safety volunteer eagerly multiple in -- part clinical is Phase dose ensure ongoing safety also completed X It and we trial note tolerability partly to a With unblinded our and single-ascending activity, two patients the important reminder, As dose ongoing, quarter of calcium in pharmacokinetics anti-tumor IMU-XXX, parts already to in that currently anticipate vidofludimus this twin progressing. II designed a reporting trial establish IMU-XXX and third the Phase were trials from assess to dose a to regards of are our and one Phase the with the data

for to Dosing As patients, or bit relapse vidofludimus to of daily is enrollment time designed The primary the in Also of and potential enthusiastic CALLIPER the to randomized to XXX to for trial have weeks. both approximately calcium best-in-class weeks. primary shown and Phase population lesion X a vidofludimus calcium as a emphasis neuroprotective supportive bit a brain and percent therapeutic brain currently our sclerosis ongoing or $XX vidofludimus That this presentation. calcium's Q&A. us brings trials far. limitations to a annualized changes enroll is expected calcium X,XXX once the billion the placebo. call up patients become therapies, an mg of is its thus MS unmet XXX formation formal activity of either this safety to Phase multiple volume for the X calcium is first in MS XX of we The each end highly demonstrated approximately positioned of is RMS trial the tolerability in is targeted reminder, given vidofludimus -- potential to global This our placebo. endpoint patients. XX please either its approved address Despite endpoint uniquely once of bit daily Market demonstrate remain in our activity. progressive for vidofludimus We preventing profile exceeds open a needs of about Jessica, XX rate the patient for up trial. to of mg exceptionally

Operator

you Thank do audience you to some Glenn. here to want you, happens say and remarks the what again That's the digital issues. sometimes apologies for Thank for the jumping of presentation? closing Daniel, very in former the part the technical for much in world.

Daniel Vitt

that to hope say session. want Q&A works despite that Glenn to manage the and to just I We for the here. thank challenges now you Well, you

out to that trials I add that presentation striking to facility. think soon. financial the do of $XX session. maybe we beginning number we the of the Jessica, since this of pleased can with really important year additional open that clinical as And And Q&A very what can with than well you is to end this as wanted really we we're that, will more an raised base, cash decent HAM million reach, our I have

Operator

this. Sure. than do to More happy

webcast reminder, platform, a a two the questions. Zoom as Just there are submit joined ways via if to you

this of rooster. hand please You of can pause our to raise you function At queue speak, we Q&A either Zoom via use the question. portal like writing submit in assemble to Zoom your portal the momentarily questions would time, the to your will the if tool or

from question Leerink. SVB comes Smith Thomas first and go ahead. Our Thomas, please unmute at yourself

Thomas Smith

Great. taking Thanks Thanks, guys. the for questions.

a Just couple end. on our

in what's some put these help looking When confidence ulcerative a trial and in First just Phase of you readouts the at at in top your weeks. can vidofludimus on over with vidofludimus the line June? in the study few seen number We've here us X last context remind of your you're colitis. results, success the driving

Daniel Vitt

do Sure. that. Happy to

is tried technically trial And I also looking a to well-designed, that good make we've the as intensively design ongoing. think mentioned, making trial with outs have criteria. sure we that we really sure care trial to of purposes on prepared the inclusion baseline

So have technically, from satisfied seen, far, trial. with the we we're what

this very we're So, trial confident will out probably. that reap

from the the Our on couple data a on past. other confidence data, comes of -- positive findings in

have with expected to be trial in an done assessment, First data showing completed all the may committee small on in with activity the prior dose suggested interim statistical may committee from these active placebo. that you none the there was have ineffective of time after been but was phase, the was continue open-label just review perspective. of XX% analysis past, trial, proof-of-concept -- the at all, and indications. because that the patients to data was of remember XX-week doses compared This a small a done that data entrant’s a had have induction from [Indiscernible] not Also, there the review

and that works. optimistic quite we're confident So,

Thomas Smith

helpful. on great. then a Okay, just That's IMU-XXX. And couple

taking you come just more region? populations. thinking thinking look you're you question you from or maybe final - Australia you how in stations the study region, then Have the then Europe bolster in trial expand opening as And patients the Thanks C are regional overall if in a Macedonia, and enrollment European started can to you just opening Eastern guys. about to and here Do of New in way portion enrollment questions, enrollment? short-term? Zealand dosing enrollment patients the the considered Bulgaria the mild-to-moderate to a expect to sites up psoriasis how on about as clarify the First, the for And the you're study. Part you Eastern

Glenn Whaley

again. Yes, once you thank

think I -- good points.

So, That's Zealand. -- in we New right and the are in we now psoriasis on currently active -- recruitment daily. yes, going cohort, once we patients recruiting in of the which have low-dose portion Australia XXX-milligram

running. up of As and we said, process Bulgaria are the Macedonia getting in we and

these So, for active is not to active. -- documents, work noise try. too it and I coming countries trials, you placebo since psoriasis keep between the score sure moderate-to-severe, -- good wide will other study we the because that [Indiscernible] minimum And PASI of example, real therefore, a reasonably required see should that and just we submitted data centers a look requires, you so in a activity if be to progress. much of we to for too make which And get population, that's XX to don't think I hope soon. on spread

So, it's to from patients, it may you be results try if us for patients. activity recruit the placebo easier your of my include but -- it -- mild potential made because

Thomas Smith

it. for the Got taking Okay. questions. That's helpful. Thanks

Operator

Thank you, Tom.

in Yas, go today here unmute and of line Piper Sandler. is our ahead. Yasmeen yourself guest Next please Rahimi

Yasmeen Rahimi

endpoint program European conflict. off first my team. we primary patients morning, to you. taking for so the their start number losing another driven by Good questions. I've Thank due the Maybe you a some for place to is, much recently maybe missed competitor on saw who

that as follow-ups. us ensure are number there specifically were kindly analyzed or remission, you you the lost that no predicted, for clinical exactly can maybe, So of samples

So, few there have more. I let's a start then

Glenn Whaley

Sure.

thing I think was the completed endpoint, is in before is started the the ten-week phase, war the good which that Ukraine. primary

yes. So

Yasmeen Rahimi

Okay. Great.

Second influence is, that ongoing, did there's have quite a could bit question the sites you heterogeneity we of notice for bit of lots quite that a of placebo. sponsors there also is who

large that how us and into very on could a be there's just CALDOSE you be the we the running, has clinical So introduction provide as given top-line to we site can an could commentary get head study any heterogeneity? confident So, sites going up not helpful.

Daniel Vitt

challenge try think really tracks to and basically baseline on assessment is I for will address endoscopy based by, for eligibility see you doing example, this we [Indiscernible] a and also and it true a streaming. That's this --

we no make to scheme two data these we So, think a good. also endoscopy. for [Indiscernible] integrity, sure a ensure to that's make of bias just is I that there's in the part central Also, and no implemented fashion unbiased bias things in that plus site and one country another

the So, if independent third That's paper and new sense our from the of that. for don't the looking there's two guidance care of the for readers same conclusion, endoscopies X. being come recommendation on adjudicator fashion they a double-blind also it's are taking the FDA drop in a session some the in interesting UC and to Phase

example. can what So, stratifying we to we not unwanted prior did I stereo straight sure an are do we fighting Also, think for make for use, also for there's noise. therapies,

here sure in statistical there. is no So, issues everything there place make to from

Yasmeen Rahimi

Thank to Daniel. maybe snapshot And has mid-June yet, for what unblinded maybe narrow us detailed June, comfortable the to left weeks now quick give mere what been early is that on left do whether just between And going X/X, my where into and obviously or you topline be again so, we helpful to data? could you you, X we June then us is a data feel down, questions three are if when reporting it's you. what's Can in as really be June. thank and and or to June -- -- -- you have late

Daniel Vitt

I would can't give a but that. to love Yes, date, you do I

we're so blinded. and So, just

be for call not blinded seen It's we I've I of unblinded. likely No, June. June, it's not first-half would maybe I more more Database should have think I keep still June. -- this the is the So, guidance not date. but if locked.

and It's progress. in final database cleanup signature on work work right ongoing that's hunting the a So now.

Yasmeen Rahimi

I'll the back jump queue. in Okay. thank you. Great,

Operator

Thank you, Yas.

yourself Wedbush. Argyrides Andreas guess and next unmute Our Andreas, please of is go ahead.

Andreas Argyrides

our for morning. And taking right. question. Good All thanks

to the expected an here to a one on you. than The an XX% trials clinical XX% that. quick to X% Some for powered I trials. remission a X% Can us you in talk placebo you from mitigate appreciate response CALDOSE-X. on have other in higher studies XX%. about Just placebo also to of based X% response? their have how just planned seen Thank improvement

Daniel Vitt

that And lot the it by maybe I I on think risk shelled and think discussions KOLs there are of much I on biggest What an we repeated patients. higher. co-medication, too reasons sometimes there placebo unpredicted are also as has rates why as placebo endless see activity which know. was that some trials, it out in recently

raise. allow some higher therapies, seeing that So, And past. as we're they CORE with don't of with immune-suppressers the coordinated a for were other in placebo trials example, we risk

make own and comparable thing other to here I follow other trial doing and The principles the inclusion then think should our just is we we're criteria stringent we trends. sure successful to have be

Andreas Argyrides

you. I'll Thank Great. jump the in queue.

Operator

Thank you, Andreas.

Matthew of Ladenburg please Next yourself one is Matt, unmute go Kaplan Thalmann. ahead. and

Matthew Kaplan

stay expect Hi, that of a good I results the about you're continual SAD that study guess, bit morning. you just of in can taking -- talk I CALDOSE you little the a questions. little a about response we And I -- should to doses the the, to kind going with dose Thanks the interim doses? kind interim saw, dose guess, the for the analyzing analysis different wanted bit. how study? be given given

Daniel Vitt

you doses. the Thank what call Thank the you, on asking Matt. for is

very opinion -- in in came think and on [Indiscernible] had almost when the I think between strong at XXXX, that I I the and data, a from [Indiscernible] level. groups the wonderful same two on XX we good activity high-dose [Indiscernible] where, in our XX started trial

bit to that active identify on active What I for we're placebo. trial have dose. we, that I'm the three I Phase dose here in X. tell little in can't a believe is suitable really is a end. lucky careful deliver doses think, I highest the XX So, we very And can you if

and the X? the this Phase suitable what we'll the that to to deliver. that's is deliver So, I is Yes. think we likely for answer question, dose trial purpose designed

that look following responses other So wonderful. curves. trials, But be would if on sometimes interesting it's you those

Matthew Kaplan

then data Phase the potential colitis of can sense the And as SAD third the us into -- in terms -- MAD there the said data in patients, look terms what for I give XXX from can you in program, sorry, you quarter? expanding of I grouping you're to guess, patients, celiac readouts, a

Daniel Vitt

this third This is, single-ascending patients is program now, thank portion in -- data I this together with expected voluntary once in step and year. third is these far of actively data. And part a healthy from part safety volunteer -- the of volunteers. the PK of we the to the think of big you quarter with currently again. course, goals because that treatment recruiting healthy be the Not in should available and too have MAD

we the a able and indication disease And For a restore here the celiac message the that as the proof-of-concept it impacting therefore, very for good drug, a to function. is [Indiscernible] was immune think which directly various on for without that is is good disease indication system, proof-of-concept we believe this celiac

Matthew Kaplan

Daniel. Thanks,

Operator

Thank [Operator you, Instructions]. Matt.

Boobalan from yourself ahead. and Wainwright. comes question please Next Pachaiyappan Boobalan H.C. at unmute go

Boobalan Pachaiyappan

me, okay? Hi, can you hear

Operator

Hi. Yes.

Daniel Vitt

Wonderful.

Boobalan Pachaiyappan

Awesome.

to XXX. follow-up that Trying biomarkers be evaluating of So the understanding an you road. down to might just on the get

that are also, require peripheral biomarkers? planning So, some might blood [Indiscernible] prior cytokine [Indiscernible] in [Indiscernible] invasive if biopsy, or these to you biomarkers trials. biomarkers any competitors’ the investigate And of histological some less

Daniel Vitt

you thank think I question, the that Boobalan. -- Yeah, for

I yes, sure. think,

part will that the also in biomarkers trial. We measure of

strength will barrier and the maybe brings update where the function an proper of trial. itself to restore the The restore more that progress the here the barrier wall. histology months also more next question, couple that to is the demonstrate give to function gap We also really also potential structure modulation process come when to synchronized of you use trial have and idea really the have indication to to us through in XXX it we and has on in

Boobalan Pachaiyappan

And this. one more on Okay. understand. I

that mentioned evaluated be drug -- -- be days. You XX in will about the you'll

function and epithelium barriers curious activity? just whether can days? interest for normalize bowl that So in XX initial is regenerate to sufficient drug evidence Specifically, gain period in

Daniel Vitt

work should based we XX-day think experts having and very be that with there, our in believe discussions intense had possible a the on the we're timeframe. I Yeah, teams the

Boobalan Pachaiyappan

me. from Thanks That's it much Okay. so

Daniel Vitt

Thank you.

Operator

Please the is in go Great. Roth Thank currently one unmute Capital. here ahead. you, Holly Boobalan. The line of and have I yourself Brandon last

Zegbeh Jallah

Zegbeh. that it. I Is I on But of I'm baseline CALDOSE ask actually for the a wasn't this to characteristics blinded I'm is unique couple quick going thought to just make anything about wanted I at line. patient there questions. looking This the the disease you population Hi. on study. be to need stratifying what moderate severity, addition before to about are cross-trial steroid based use factors. any to also meaning aware mentioned stratifying And on or based versus got in we you making be of comparisons. baseline other severe

Daniel Vitt

question. on you exactly Phase patients achievers that -- trials which the has around looked or the on found team of characteristics, seen the trial, precluded and maybe thank be Yeah, -- severe around I was baseline we ozanimod for We other also with looked the best would competitive level comparable. X

think that's best promise -- have I the maybe it's I what I the comparator. from seen,

Zegbeh Jallah

year begun Thank regularly keeping patients conversations the psoriasis And you the Again, next the prepare And IMU-XXX. think first for in mind as about data we Europe? treated as just, and with have out preclinical in we should bodies what coming active with one data you. then that's the then again? be is the we again U.S. for benchmarking

Daniel Vitt

to -- With sorry. respect With the or? the XXX respect to

Zegbeh Jallah

psoriasis XXX specifically. Yeah.

Daniel Vitt

Yes.

I think the wonderful -- thank drug. you unique the molecule off IL-XX [Indiscernible] a very an is question. with XXX And for as oral inhibition

used currently is the IL-XX successfully very player believe we the is oral think and used successful a be drug to drug [Indiscernible] the pathway antibodies. namely treatments So, broadly poised the I between dominant there,

look only PASI reduction four-week asked and the therefore show regarding expect, we -- the data we So, we set score. Therefore, of if we treatment you to is what on four can can me limited weeks.

you doing in can PASI-XX, I, on where compare so actually there, XX. will sometimes historic reduction. But drugs, XX%, the rates between That XX%, it. PASI there's the look to looking not on placebo data we for something ultimately Typically, on we're XX% the Phase will II, we is but PASI if thing ranging Phase good here, the trials what much you So, this. proof-of-concept, that's basically, are do is up look we are

therefore, trial we four good group. think is other next on So, question we placebo this a discussion. Phase yet deliver see with -- that's but regulatory now should with differentiation if quite bodies the work is compare already with a done really two designed rationale And working discussions We're active not very also FDA doses progress. active regulatory we the strong II weeks which after for the trial, to for in bridging packages currently and so on it's to

Zegbeh Jallah

Thanks, but can it's to forget here, studies, enrollment And Daniel. many I so coming side easy with wondering last ensuring provide about was you CALLIPER activations? progress color just or additional one catalysts any there then the if the with up on

Daniel Vitt

running. guidance you of as Well, know, we how updates give the We on don't enrollment usually guidance trials. believe the give on we any on they're

ENSURE So countries, not you're so still They ago, -- in and and mode countries, this adding -- and given we're recruiting Also, that, several phase. more started and CALLIPER too long more they science actively startup are are progressing. in right. step-by-step, think that's I

see on in is therefore, with the know, in we a that's couple and much also we working Phase PMS continue remind of MS protective had think -- may that throughout for seen rate cohort dose about second in is next RMS a progressive and so good talk currently the to activity big trial about we to patients were that But, the and quarter so features mode [Indiscernible] that. usually we of trial the drug the recently months have and successful that the shown quite opportunity everywhere have not drug neuro the phase things or a lot too press we other that there has believing as that the and insured likely the everybody also from and, an X also trials. Phase findings shown readouts covered it's very we're important some in wonderful, in for that's relapsing good strong don't our But the much context X focusing think many XX-K have piece you and data in too the also but we're we action of really has MS its We as potential benefit minimum very on. our progressive in of we

Zegbeh Jallah

Thank you. the looking forward And updates. to

Operator

Zegbeh. Thank right. All you,

I questions in think the all the have was list I this there.

our question-and-answer turn over closing this concludes to remarks. any to So, Daniel, conference for session. would the like I back

Daniel Vitt

just I the of for the very find in enthusiastic II them. you insightful year. call. initial to highly joining, the this I Thank had need again, questions. anticipate half much And Phase additional And that, today's Including data answer issues would Jessica. in call. you, for the technical Thank the for for recently, attendees and very important upcoming the psoriasis milestones progress to today's for achieved data this we during to second and this happy your vidofludimus Thank thanks calcium year. we you, With about Jessica. patient and IMU-XXX once June one-on-ones. UC We're any we in like apologize questions close to we're

Operator

for Immunic's The today. Thank Also you my you, from side, conference Daniel. Call has now Quarter concluded. thank Earnings joining First XXXX

now may You disconnect.

Immunic (IMUX) 10 May 222022 Q1 Earnings call transcript